title: Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress.
abstract: Endothelin (ET) was first isolated and described by Yanagisawa et al. and has since been described as one of the most potent known vasoconstrictor compounds. ET-1 mediates its effects via two types of receptors, ETA and ETB, which are expressed in the vascular smooth muscle cells, endothelial cells, intestines and brain. Secretion of ET-1 results in long-lasting vasoconstriction, increased blood pressure and, in turn, overproduction of free radicals. As dysregulation of the endothelin system is an important factor in the pathogenesis of several diseases including atherosclerosis, hypertension and endotoxic shock, the ETA and ETB receptors are attractive therapeutic targets for treatment of these disorders. The biosynthesis and release of ET-1 are regulated at the transcriptional level. Studies have shown that p38MAP kinase, nuclear factor kappaB (NF-kappaB), PKC/ERK and JNK/c-Jun all take part in the ROS-activated production of ET-1. Furthermore, administration of ET(A) significantly reduces the generation of free radicals. However, treatment with ETB receptor blockers does not elicit the same effect. Therefore, the effects of endothelin receptor blockers on blood pressure and the generation of free radicals remain debatable. This review summarizes recent investigations into the role of endothelin receptor blockers with respect to the modulation of hemodynamic parameters and the generation of free radicals.
authors.affiliation: Chair of Experimental and Clinical Physiology, Department of Cardiovascular Physiology, Medical University of Łódź, Mazowiecka 6/8, PL 92-215 Łódź, Poland. piechota.aleksandra@wp.pl
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Piechota
authors.forename: Andrzej
authors.initials: A
authors.lastname: Polańczyk
authors.forename: Anna
authors.initials: A
authors.lastname: Goraca
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000096:biosynthesis / Q000502:physiology; D005609:Free Radicals / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects*; D017466:Receptors, Endothelin / Q000378:metabolism / Q000502:physiology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D005609:Free Radicals; D017466:Receptors, Endothelin